Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Hyalgen** is a topical nanoparticle-based dermatology and aesthetic skin care serum developed by **Endor Nanotechnology** for professional use as an adjuvant to facial aesthetic procedures. The product is described as containing **Gold Thioethylamino Hyaluronic Acid** consisting of low molecular weight hyaluronic acid-coated gold nanoparticles, with reported particle dimensions of about 10 nm gold cores and roughly 22 nm final particles. Its proposed mechanism is targeted interaction of the hyaluronic acid-coated nanoparticles with **CD44**, with downstream stimulation of endogenous hyaluronic acid, collagen, and elastin production to improve skin firmness and reduce fine lines and wrinkles. Hyalgen appears to have been positioned as a cosmeceutical or dermatology product used topically in combination with radiofrequency and other aesthetic procedures such as HIFU, microneedling, and plasma pen treatments rather than as a conventional approved pharmaceutical therapeutic.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Hyalgen.